Metastatic neoplasm

This study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This phase 2 trial is testing whether adding two extra drugs—bevacizumab and sintilimab—to the usual combination of irinotecan and cetuximab can shrink tumors in people with advanced colorectal cancer that no longer responds to irinotecan. The study enrolls 160 adults with RAS wi…

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This phase 2 trial tests whether adding cediranib or ceralasertib to olaparib can overcome resistance in BRCA-mutated advanced breast cancer. About 60 participants with HER2-negative, BRCA-positive tumors that have progressed on prior therapy will receive one of the two drug comb…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This phase 2 trial compares a new type of radiation called LATTICE radiotherapy with standard palliative radiation for people who have large metastatic tumors (over 2.5 cm). The LATTICE method delivers a very high dose to the center of the tumor while keeping lower doses to the s…

This global study is testing whether adding the experimental drug olomorasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the ne…

This large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and CDK4/6 inhibitors can better control advanced HR+ HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The goal i…

This early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a small dose of radiation to help …

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

This Phase 2 trial tests whether combining two oral drugs, luvometinib and anlotinib, can shrink tumors in people with KRAS-mutated non-small cell lung cancer that has spread and stopped responding to prior treatment. About 48 adults will receive different dose combinations. The …

This study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the best dose and check if it is safe and shrinks tumors. All participants get the drug by injection, and the study invol…

This early-stage trial tests a new drug called CBP-1019 combined with standard chemotherapy (FOLFOX) and possibly other drugs for people with advanced solid tumors that have not responded to prior treatments. The goal is to find safe and effective doses. About 128 participants wi…

This study tests an experimental drug called NEOK002 in people with advanced solid tumors that have spread and cannot be removed by surgery. The drug is designed to target two proteins on cancer cells to deliver a toxic payload. The study has two parts: first, finding the safest …

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

This study tests whether adding a new targeted medicine (vepugratinib) to two standard cancer drugs can help people with advanced bladder cancer that has a specific genetic change (FGFR3). About 450 adults whose cancer has spread or cannot be removed by surgery will take part. Th…

This early-stage trial is testing a new oral drug called LOXO-435, alone or with other cancer medicines, in people with advanced solid tumors that have a specific change in the FGFR3 gene. The study aims to find the right dose and check for safety and early signs of effectiveness…

This study tests whether two drugs, zanzalintinib and pembrolizumab, can help control advanced soft-tissue sarcoma that has spread. About 20 adults with specific sarcoma types will receive the combination. The main goal is to check safety and see if the treatment slows tumor grow…

This study looks at how well sacituzumab tirumotecan (SKB264) works, either alone or with other treatments, in people with advanced HER2-negative breast cancer that has spread or come back. It includes two groups: those with triple-negative breast cancer and those with hormone re…

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …

This phase I/II trial tests whether injecting NBTXR3 nanoparticles into tumors can make radiation more effective, combined with immunotherapy (anti-PD-1/PD-L1), for patients with advanced solid cancers that have spread to the lung or liver. The study aims to see if this approach …

This phase II trial is testing whether continuing targeted therapy or immunotherapy based on a tumor's molecular profile can benefit patients with advanced solid tumors that have stopped responding to prior treatment. After an initial treatment period, patients whose disease is s…

This phase IIa trial tests a combination of a dendritic cell vaccine (targeting HER2/HER3 proteins) and the immunotherapy drug pembrolizumab (Keytruda) in 23 women with breast cancer that has spread to the brain. The vaccine aims to train the immune system to attack cancer cells,…

This early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…

This study looks at two types of hip surgery for people whose cancer has spread to the hip bone. One surgery removes the damaged bone and replaces it with an artificial joint. The other uses metal rods and plates to hold the bone together. The goal is to see which surgery leads t…

This phase 2 trial tests whether giving focused radiation (SBRT) to a few growing prostate cancer spots, while staying on current therapy, can control the cancer better than switching to a new systemic therapy. About 75 men with castration-resistant prostate cancer that has a lim…

This study compares two radiotherapy schedules for men whose prostate cancer has returned after surgery. The standard treatment takes 5 weeks, while the shorter one takes 4 weeks. Researchers want to see if the shorter schedule causes no more side effects and controls the cancer …

This Phase II trial is testing a combination of three drugs—zanidatamab, pembrolizumab, and chemotherapy—in 80 people with advanced stomach or esophageal cancer that has spread and tests positive for HER2 and PD-L1. The goal is to see if this triple therapy can keep the cancer fr…

This expanded access program provides vepugratinib, an oral drug, to people with metastatic urothelial carcinoma or other solid tumors that have a specific FGFR3 genetic change. Participants must have exhausted other approved treatments, including erdafitinib for bladder cancer, …

This early-stage study tests a personalized radiation technique called PULSAR for lung cancers located near the center of the chest. The goal is to make treatment safer while still effectively controlling the tumor. About 30 adults with primary or metastatic lung cancer will rece…

This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…

This study is for people with stage IV cancer that has started to grow in only a few places (oligoprogression). It compares adding local treatments like radiation or surgery to all growing spots versus switching to a new systemic therapy. The goal is to see if this approach can b…

This study tests a new treatment using specially engineered natural killer (NK) cells to attack advanced lung cancer that has spread. About 60 adults whose tumors have certain markers will receive chemotherapy followed by an infusion of these cells. The goal is to find a safe dos…

This phase 2 trial tests the drug avapritinib in 50 adults with advanced solid tumors that have mutations in the CKIT or PDGFRA genes. The drug blocks enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also…

This study tests two different chemotherapy combinations for people with metastatic colorectal cancer that has spread and needs a second treatment. About 280 adults will be randomly assigned to receive either FOLFIRI or irinotecan, with or without bevacizumab. The goal is to see …

This early-phase trial is testing a new type of cell therapy for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered natural killer (NK) cells that target two proteins found on cancer cells. Up to 42 part…

This study combines two treatments—laser heat to destroy tumors near the spinal cord and precise radiation—to better control spine tumors that have spread from other cancers. About 60 adults with solid tumors will receive both therapies. The goal is to improve tumor control, redu…

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…

This phase 1 trial is testing whether injecting tiny radioactive beads (Y-90) into the right side of the liver can shrink tumors and make the left side grow larger, so more patients with colorectal cancer liver metastases can have potentially curative surgery. The study will enro…

This early-phase trial is testing whether a combination of two drugs, atezolizumab and tiragolumab, can help control bladder cancer when given before surgery to remove the bladder and tumor. The study includes 10 adults with muscle-invasive bladder cancer who cannot take standard…

This phase 2 trial is testing the safety of abemaciclib (Verzenio) combined with hormone therapy in people aged 70 and older with hormone receptor-positive metastatic breast cancer that has worsened after prior treatment with a similar drug. The study will enroll 43 participants …

This study is for people with endometrial cancer that has come back or spread to a few other spots. It tests a new drug called cadonilimab given together with standard chemotherapy and radiation. The goal is to see if this combination can shrink tumors and help people live longer…

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This study tests two drugs, abemaciclib and bicalutamide, together in people with a type of metastatic breast cancer that has spread and is positive for androgen receptors but negative for HER2. The goal is to find the safest dose and see if the combination can control the diseas…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This study tests whether adding four drugs (gefitinib, trametinib, disulfiram, and sunitinib) to standard chemotherapy helps people with osteosarcoma that has spread. About 45 participants with newly diagnosed or advanced disease will be enrolled. Researchers will check if the co…

This study tests whether adding the drug sarilumab to chemotherapy (capecitabine) can eliminate tiny amounts of cancer left behind after standard treatment in people with triple negative breast cancer, a very aggressive type. The goal is to prevent the cancer from coming back and…

This study tests a procedure called chemoembolization for people with non-small cell lung cancer or lung tumors that have spread from other cancers. Doctors inject chemotherapy directly into the artery feeding the tumor and then block that artery with tiny beads. This traps the c…

This phase 2 study is testing stereotactic body radiation therapy (SBRT) for people with non-small cell lung cancer or other cancers that have spread to the lung. Instead of daily radiation for weeks, participants receive high doses in just 3 to 10 sessions over 1 to 2 weeks. The…

This study is for people with metastatic melanoma whose cancer has started growing in a few spots despite treatment. Researchers want to see if giving high-dose, precise radiation to those spots can delay further spread. About 52 adults will take part, and the main goal is to see…

This phase 2 trial tests whether giving precise radiation (SBRT) to a few growing cancer spots can help women with ER+/HER2- metastatic breast cancer stay on their current hormone therapy or CDK4/6 inhibitor longer. The study enrolls 48 women whose cancer has started to progress …

This early-stage trial tests the safety of combining two drugs, ONC201 and atezolizumab, in 58 women with advanced or recurrent endometrial cancer. The study includes both obese and non-obese participants to see if body weight affects treatment. The goal is to find the best dose …

This early-phase trial is testing a personalized vaccine made from a patient's own tumor, given alone or with immune-boosting drugs (pembrolizumab or ipilimumab), for triple negative breast cancer. The goal is to see if the vaccine is safe and can train the immune system to attac…

This study is testing a procedure called radiation segmentectomy for adults with liver cancer. Doctors deliver tiny radioactive resin beads directly to the tumor's blood supply to kill cancer cells while sparing healthy tissue. The goal is to find the best radiation dose for comp…

This study tests a new gel called INT001 that is injected directly into liver tumors to kill them. About 31 adults with liver cancer who cannot have surgery will receive one injection and be followed for 90 days. The goal is to see if the gel safely destroys the tumor and what si…

This phase III trial tests whether adding stereotactic ablative radiotherapy (SABR) to standard treatment (chemotherapy, hormone therapy, or palliative radiation) improves survival in adults with 1 to 10 metastatic tumors and an active primary cancer. About 180 participants will …

This study tests a new way to treat small lung tumors by freezing them. Doctors use a special scope to guide a freezing probe directly to the tumor. The trial includes 40 adults with early-stage or limited metastatic lung cancer. The goal is to see if the procedure is safe and ca…

This early-stage trial is testing an experimental drug called RBS2418, taken as a pill, to see if it can help the immune system fight advanced cancers that have spread or come back. The study involves 164 adults with various solid tumors who have already tried standard treatments…

This study tests a combination of three drugs (surufatinib, sintilimab, and capecitabine) in people with advanced small bowel or appendix cancer that has spread and stopped responding to standard treatments. The goal is to see if this mix can shrink tumors or slow cancer growth. …

This study compares carbon fiber and titanium screws in people with cancer that has spread to the spine. The goal is to see if carbon screws cause fewer imaging problems, making it easier to plan radiation therapy and spot cancer return. About 226 adults will take part, and the s…

This study tests whether a precise, high-dose radiation technique called SABR works better than standard palliative radiation for people whose cancer has spread to a few new spots while on treatment. About 194 adults with solid tumors (excluding lymphoma or myeloma) and up to 5 g…

This early-phase trial tests a new therapy called NW-101C, which uses a patient's own immune cells (T cells) that have been genetically modified to recognize and attack cancer cells carrying a protein called PRAME. The study will enroll 24 adults with advanced solid tumors that h…

This early-phase trial is testing a new approach called Peptide Alarm Therapy (PAT) for people with advanced solid tumors that have not responded to at least one prior treatment, including immunotherapy. PAT is injected directly into a tumor along with a standard PD-1 inhibitor d…

This early-phase study tests a new drug called SIM0609 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 232 participants will take part a…

This early-stage trial is testing a new three-drug combination for people with head and neck cancer that has come back or spread. The drugs include a targeted therapy (zanzalintinib), an immunotherapy (pembrolizumab), and another targeted antibody (cetuximab). The main goal is to…

This early-phase study tests a technique called in vivo lung perfusion (IVLP) that delivers chemotherapy directly into the lung during surgery to remove sarcoma tumors that have spread to the lungs. The goal is to kill any tiny cancer cells left behind that could cause the cancer…

This study tests whether adding an immune-boosting drug (IMSA101) and targeted radiation to standard immunotherapy can help control metastatic kidney cancer that has started to grow again. About 15 adults with clear cell kidney cancer that has progressed in up to 5 spots will rec…

Researchers are testing whether a single injection of a radioactive tracer, followed by a PET/CT scan, can clearly show primary tumors and any spread in adults with suspected or known SSTR-related cancers. The study will measure how well the tracer highlights lesions and calculat…

Researchers are testing whether a new PET/CT imaging agent, 68Ga/18F-Pentixafor/Pentixather, can accurately detect primary tumors and metastases in people with CXCR4-related diseases, including certain lymphomas and other cancers. The study will enroll 200 participants who have s…

Researchers are testing whether a radioactive tracer called 68Ga/18F-PSMA/PSFA can improve PET/CT scans for finding tumors in people with PSMA-related cancers, including prostate and liver cancer. The study will enroll 500 adults with suspected, newly diagnosed, or previously tre…

This trial tests whether a new imaging tracer called FAPI, used with PET/CT scans, can better detect primary tumors and metastases in people with FAP-related diseases. Researchers will give participants a single injection of the tracer and then perform imaging to measure how much…

This early-phase trial is testing whether a new imaging agent called SLR-108 can improve PET scans for people with metastatic solid tumors. SLR-108 is an antibody that carries a small amount of radioactivity and is designed to attach to tumor cells, making them more visible on a …

This trial evaluates a radioactive tracer called 68Ga-DOTA/NOTA-FAPI-04, given as a single injection before a PET/CT scan, to see if it can better identify primary tumors and metastases in people with various cancers. Researchers will measure how strongly the tracer accumulates i…

This study compares a special PET scan (68Ga-PSMA) with standard CT scans to see which better detects where kidney cancer has spread in 300 adults with advanced disease. Participants will receive both scans, and doctors will check if the PET scan changes treatment plans. The goal…

This study tests a special dye that makes cancer cells glow when applied to lymph nodes removed during breast cancer surgery. The goal is to help surgeons instantly tell if a sentinel lymph node contains cancer, so they only remove the nodes that are truly affected. The trial wil…

This phase 2 trial tests whether a higher dose of radiation (40-50 Gy over 10 sessions) can better relieve pain from cancer that has spread to bones or other areas. Researchers hope to double the complete pain response rate at one month compared to standard doses. The study invol…

This early trial tests whether minoxidil (Rogaine) — applied to the scalp or taken as a pill — can help with hair loss caused by hormone therapy in breast cancer patients. About 50 women with stage I-IV breast cancer who report hair thinning since starting endocrine therapy will …

This study looks at how well a special implant (IlluminOss) works for people with pelvic fractures from cancer that has spread or from aging. The goal is to see if it reduces pain and helps patients move better. About 100 adults will be followed for up to 2 years after surgery, r…

This study compares three types of radiation therapy for cancer that has spread to the spine, with the goal of relieving pain. About 240 participants will be randomly assigned to receive either standard external beam radiation, standard-dose stereotactic body radiation, or higher…

This study is observing about 800 adults with advanced breast cancer (HER2-positive, low, or ultralow) who are receiving the drug trastuzumab deruxtecan as part of their normal care in Germany. Researchers are tracking how long patients stay on the drug before switching treatment…

This study is testing whether a smartwatch can track changes in walking and daily activities in people with bone cancer (osteosarcoma or metastatic bone disease). The goal is to see if the watch can help doctors spot problems early and personalize care. About 60 participants will…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study is testing whether wearing a fitness tracker (like a Fitbit) can give doctors a better picture of how active cancer patients are, and whether that activity level relates to how well they are doing overall. About 590 people with various cancers will wear activity monito…

This study is testing whether using simple blood tests to decide when to do scans is as effective as the usual approach of regular scans for people with advanced breast cancer. About 739 participants will be randomly assigned to either blood test monitoring or standard care. The …

This study looks at people with small intestinal neuroendocrine tumors that have spread and cannot be cured. It compares those who had surgery to remove the main tumor plus other treatments against those who had only other treatments. The goal is to see if surgery helps patients …

This study looks back at medical records of 350 people with cervical cancer that has come back or spread to a few spots. The goal is to see how well treatments like radiation or surgery work, alone or with chemotherapy. Researchers want to find out which patients benefit most fro…

This study looks at how much radiation reaches tumors and healthy organs during a treatment called 177Lu-PSMA-617 for advanced prostate cancer that has spread. Researchers want to see if the radiation dose can predict how well the treatment works and what side effects might occur…

This study is tracking 3000 men with prostate cancer from Guadeloupe and Brittany to understand why the disease progresses differently in different people. Researchers will collect blood, urine, and saliva samples along with health data to look for genetic, environmental, and lif…

This study follows 700 adults with advanced or metastatic breast cancer who are taking CDK4/6 inhibitors (ciclib drugs). Researchers collect blood, tissue, and fluid samples to understand how the cancer responds, why resistance develops, and how well patients do over time. The go…

This study aims to find genetic and immune changes that help lung cancer start and grow. Researchers will collect tissue samples from 6,000 people with lung cancer or suspicious lung masses. The goal is to better understand the disease, not to test a new treatment.